Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2013-09-23 Annual Report
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Annual Report to shareholders 86 pages 1.6MB
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2013' and contains detailed sections typical of a full annual report, including Chairman's letter, Directors' Report, Remuneration Report, Auditor's Independence Declaration, Corporate Governance Statement, and comprehensive financial statements such as Consolidated Statement of Profit and Loss, Financial Position, Cash Flows, Equity, and Notes to the Financial Statements. It also includes an Independent Auditor's Report and ASX Additional Information. The content covers the full fiscal year ended 30 June 2013, with detailed operational and financial information, acquisitions, and outlook. The document length is substantial (15,000 characters), indicating it is the full report rather than an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2013
2013-09-23 English
MYX announces US agreement for Itraconazole in Cancer 3 pages 328.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 11 September 2013, detailing Mayne Pharma's exclusive US license and supply agreement with HedgePath Pharmaceuticals for SUBA™-Itraconazole in cancer treatment. It discusses the terms of the agreement, strategic collaboration, and background on the drug and companies involved. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is a corporate announcement about a licensing and supply agreement, which relates to capital and financing activities or strategic partnerships. It is not a full financial report, earnings release, or regulatory filing of financial results. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (8310 characters) supports it being a detailed announcement rather than a brief notice or report publication announcement.
2013-09-10 English
Mayne Pharma appoints leader of USA operations 2 pages 234.6KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 6 September 2013 about the appointment of a new leader for the company's USA operations. It details the new President's background, responsibilities, and the transition from the previous executive. There is no financial data, no mention of a report or filing, and the content focuses solely on management changes. This fits the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2013-09-05 English
2013 Full Year Results Appendix 4E 26 pages 890.0KB
Annual Report Classification · 95% confidence The document is titled 'Mayne Pharma Group Preliminary Final Report and accompanying announcement' and includes an Appendix 4E Preliminary Final Report for the year ended 30 June 2013. It contains detailed financial statements such as consolidated statements of profit or loss, comprehensive income, financial position, cash flows, and changes in equity. The report discusses operating performance, acquisitions, tax, cash flow, and dividend information for the full fiscal year ending 30 June 2013. The length of the document is substantial (15,000 characters), and it contains actual financial data and analysis rather than just an announcement or certification. The Appendix 4E is a recognized Australian reporting format for preliminary final reports, which is equivalent to an annual report or full year financial report. Therefore, this document is best classified as an Annual Report (10-K equivalent). FY 2013
2013-08-26 English
2013 Full Year Results Media Release 5 pages 415.4KB
Annual Report Classification · 95% confidence The document is an ASX announcement dated 27 August 2013 reporting the full year ended 30 June 2013 financial results of Mayne Pharma Group Limited. It contains detailed financial data including sales revenue, EBITDA, net profit after tax, segment performance, cash flow details, and outlook commentary. The document discusses actual financial results for the fiscal year, compares them to guidance, and provides operational and strategic updates. It is not merely an announcement of a report or a certification but contains substantive financial data and analysis for the full fiscal year. Therefore, it fits the definition of an Annual Report (10-K equivalent) or a full year financial results report. Given the Australian context and ASX announcement format, this is best classified as an Annual Report (10-K) type filing rather than a short Earnings Release or Regulatory Filing. Confidence is high due to the detailed financial content and comprehensive coverage of the fiscal year results. FY 2013
2013-08-26 English
2013 Full Year Results Investor Presentation 18 pages 1.2MB
Investor Presentation Classification · 95% confidence The document is titled 'FY13 Results Presentation' and dated 27 August 2013, indicating it is a presentation of the full fiscal year 2013 financial results. It contains detailed financial data such as revenue, EBITDA, NPAT, segment sales breakdowns, and outlooks. The document includes forward-looking statements, non-IFRS financial information, and extensive discussion of business segments and product pipelines. The length is about 15,000 characters, which is substantial and contains actual financial data and analysis. The content is consistent with an investor presentation focusing on financials, strategy, and market position rather than a formal annual report or earnings release. It is not a brief earnings release (which would be shorter and less detailed), nor is it a regulatory filing or certification. Therefore, the document best fits the category of an Investor Presentation (IP).
2013-08-26 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.